US Patent No: 5,851,996

Number of patents in Portfolio can not be more than 2000

Materials and methods for treatment of plaquing diseases

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

Methods and compositions are provided for alleviation of disease states involving plaque formation, such as are manifested in Alzheimer's Disease and other amyloid disorders, and arteriosclerotic disease. Methods for the treatment of herpes virus infections by administration of thimerosal are further provided by the invention.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
MILKHAUS LABORATORY, INC.DELANSON, NY34

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kline, Ellis L Pendleton, SC 13 201

Cited Art

Patent Info (Count) # Cites Year
 
MILKHAUS LABORATORY, INC. (2)
4,880,626 Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome 25 1987
5,753,624 Materials and methods for treatment of plaquing disease 71 1996
 
MOLECULAR RX, INC. (2)
4,294,818 Methods and materials for detection of multiple sclerosis 21 1979
4,704,273 Methods and materials for treatment of rheumatoid arthritis 18 1986
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (2)
4,912,206 CDNA clone encoding brain amyloid of alzheimer's disease 33 1987
5,276,059 Inhibition of diseases associated with amyloid formation 53 1992
 
SCIOS NOVA INC. (2)
5,223,482 Recombinant Alzheimer's protease inhibitory amyloid protein and method of use 30 1989
5,187,153 Methods of treatment using Alzheimer's amyloid polypeptide derivatives 69 1990
 
SIGNAL COORDINATING THERAPY, INC. (2)
4,521,405 Methods and materials for treatment of disease states involving immunological factors 9 1982
4,705,685 Methods and materials for treatment of disease states involving immunological factors 14 1985
 
DMS PHARMACEUTICAL INC. (1)
4,816,416 Microspheric bodies for use in screening therapies for Azheimer's disease and related conditions 18 1987
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
4,666,829 Polypeptide marker for Alzheimer's disease and its use for diagnosis 234 1985

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (30)
6,787,523 Prevention and treatment of amyloidogenic disease 46 1998
7,964,192 Prevention and treatment of amyloidgenic disease 1 1999
6,761,888 Passive immunization treatment of Alzheimer's disease 55 2000
6,913,745 Passive immunization of Alzheimer's disease 37 2000
6,710,226 Transgenic mouse assay to determine the effect of A.beta. antibodies and A.beta. Fragments on alzheimer's disease characteristics 38 2000
7,588,766 Treatment of amyloidogenic disease 8 2000
7,575,880 Method of screening an antibody for activity in clearing an amyloid deposit 8 2000
6,905,686 Active immunization for treatment of alzheimer's disease 32 2000
6,890,535 Pharmaceutical compositions and methods for treatment of amyloid diseases 32 2000
6,875,434 Methods of treatment of Alzheimer's disease 35 2000
6,787,138 Prevention and treatment of amyloidogenic disease 36 2000
6,787,139 Prevention and treatment of amyloidogenic disease 33 2000
6,787,140 Prevention and treatment of amyloidogenic disease 35 2000
6,787,143 Prevention and treatment of amyloidogenic disease 29 2000
6,787,144 Prevention and treatment of amyloidogenic disease 36 2000
6,787,637 N-Terminal amyloid-.beta. antibodies 47 2000
6,750,324 Humanized and chimeric N-terminal amyloid beta-antibodies 46 2000
6,743,427 Prevention and treatment of amyloidogenic disease 69 2000
7,014,855 Prevention and treatment of amyloidogenic disease 29 2004
6,866,849 Prevention and treatment of amyloidogenic disease 37 2004
6,866,850 Prevention and treatment of amyloidogenic disease 35 2004
6,818,218 Prevention and treatment of amyloidogenic disease 27 2004
6,808,712 Prevention and treatment of amyloidogenic disease 25 2004
6,962,707 Prevention and treatment of amyloidogenic disease 28 2004
8,034,339 Prevention and treatment of amyloidogenic disease 0 2004
6,972,127 Prevention and treatment of amyloidogenic disease 35 2004
6,946,135 Prevention and treatment of amyloidogenic disease 27 2004
7,790,856 Humanized antibodies that recognize beta amyloid peptide 1 2006
8,034,348 Prevention and treatment of amyloidogenic disease 0 2007
7,893,214 Humanized antibodies that recognize beta amyloid peptide 0 2007
 
WYETH LLC (9)
7,189,819 Humanized antibodies that recognize beta amyloid peptide 25 2001
7,582,733 Humanized antibodies that recognize beta amyloid peptide 10 2002
7,256,273 Humanized antibodies that recognize beta amyloid peptide 29 2003
7,179,892 Humanized antibodies that recognize beta amyloid peptide 30 2003
7,871,615 Humanized antibodies that recognize beta amyloid peptide 1 2004
7,625,560 Humanized antibodies that recognize beta amyloid peptide 5 2005
7,700,751 Humanized antibodies that recognize β-amyloid peptide 1 2007
8,128,928 Humanized antibodies that recognize beta amyloid peptide 0 2007
8,003,097 Treatment of cerebral amyloid angiopathy 0 2008
 
BIOARCTIC NEUROSCIENCE AB (5)
8,106,164 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 1 2005
7,700,719 Arctic β amyloid protofibril 1 2007
8,025,878 Protofibril selective antibodies and the use thereof 1 2007
8,409,575 Antibodies specific for amyloid beta protofibril 0 2011
8,404,459 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 0 2011
 
RINAT NEUROSCIENCE CORP. (5)
7,927,594 Antibodies directed against amyloid-beta peptide 1 2005
7,807,165 Antibodies directed against amyloid-beta peptide and methods using same 2 2005
7,763,250 Antibodies directed against amyloid-beta peptide and nucleic acids encoding same 1 2006
8,398,978 Antibodies directed against amyloid-beta peptide and methods using same 0 2010
8,268,593 Polynucleotides encoding antibodies directed against amyloid-beta peptide 0 2010
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (4)
7,727,957 Treatment and delay of outset of Parkinson's disease 2 2003
7,919,088 Treatment and delay of onset of synucleinopathic and amyloidogenic disease 0 2007
8,147,833 Prevention and treatment of synucleinopathic and amyloidogenic disease 0 2008
8,092,801 Prevention and treatment of synucleinopathic and amyloidogenic disease 0 2008
 
CROSSBETA BIOSCIENCES B.V. (3)
8,114,832 Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition 0 2005
8,067,187 Cross-β structure binding compounds 0 2006
8,158,585 Cross-β structure comprising amyloid-binding proteins and methods for detection of the cross-β structure, for modulating cross-β structures fiber formation and modulating cross-β structure-mediated toxicity 0 2007
 
ELAN PHARMACEUTICALS, INC. (3)
7,674,599 Methods of using antibodies to detect alpha-synuclein in fluid samples 3 2004
7,977,316 Prevention and treatment of amyloidogenic diseases 0 2007
7,910,333 Antibodies to alpha-synuclein 2 2010
 
WASHINGTON UNIVERSITY (3)
7,771,722 Assay method for alzheimer's disease 0 2002
7,195,761 Humanized antibodies that sequester abeta peptide 22 2002
7,892,545 Humanized antibodies that sequester amyloid beta peptide 0 2008
 
APPLIED MOLECULAR EVOLUTION, INC. (2)
7,575,747 Aβ binding molecules 1 2004
8,105,597 Aβ binding molecules 0 2009
 
NEOTOPE BIOSCIENCES LIMITED (2)
6,923,964 Active immunization of AScr for prion disorders 24 2000
8,124,081 Prevention and treatment of amyloidogenic diseases 0 2007
 
NEUROCHEM (INTERNATIONAL) LIMITED (2)
7,060,670 Stereoselective antifibrillogenic peptides and peptidomimetics thereof 1 2000
7,288,523 Peptide binding the KLVFF-sequence of amyloid-.beta. 0 2003
 
AUCKLAND TECHNOLOGY ENABLING CORPORATION LIMITED (1)
7,935,333 Method and compositions for modifying target receptor function associated with neurological disorders 0 2004
 
ELAN PHARMA INTERNATIONAL LIMITED (1)
6,936,246 Passive immunization of ASCR for prion disorders 6 2000
 
ELI LILLY AND COMPANY (1)
8,066,999 PEGylated Aβ fab 0 2008
 
GEMVAX AS (1)
6,861,057 Immunogenic .beta.-amyloid peptide 11 2001
 
H. LUNDBECK A/S (1)
7,135,181 Method for down-regulation of amyloid 5 2001
 
INTELLECT NEUROSCIENCES INC. (1)
8,173,127 Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof 0 2002
 
NOVARTIS PHARMA AG (1)
7,320,793 Molecular antigen array 2 2002
 
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (1)
8,105,594 Methods for amyloid removal using anti-amyloid antibodies 0 2010